Formulation and evaluation of ubidecarenone transdermal delivery systems

References

• Ernster L, Dallner G. (1995). Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta, 1271:195–204.
   PubMed Web of Science ®Google Scholar
• Bhagavan HN, Chopra RK. (2006). Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Res, 40:445–53.
   PubMed Web of Science ®Google Scholar
• Crane FL. (2001). Biochemical functions of coenzyme Q10. J Am Coll Nutr, 20:591–8.
   PubMed Web of Science ®Google Scholar
• Beal AM. (2002). Coenzyme Q10 as a possible treatment for neurodegenerative disease. Free Rad Res, 36:455–60.
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. (1999). Overview of the use of coenzyme Q10 in cardiovascular disease. Biofactors, 9:273–84.
   PubMed Web of Science ®Google Scholar
• Liannane AW, Eastwood H. (2004). Cellular redox poise modulation: The role of coenzyme Q10, gene and metabolic regulation. Mitochondrion, 4:779–89.
   PubMed Web of Science ®Google Scholar
• Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. (1999). Coenzyme Q10 in health and disease. Eur J Clin Nutr, 53:764–70.
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. (1998). Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischemia. Asia Pac Heart J, 7:160–8.
   Google Scholar
• Schultz CW, Oakes D, Kieburtz K, Beal FL, Haas R, Plumb S, , the Parkinson Study Group. (2002). Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol, 59:1541–50.
   PubMed Web of Science ®Google Scholar
• Miles MV. (2007). The uptake and distribution of coenzyme Q(10). Mitochondrion, 7S:72–7.
   Google Scholar
• Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. (1998). Relative bioavailbility of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res, 68:109–13.
   PubMed Web of Science ®Google Scholar
• Miles MV, Horn P, Miles L, Tang P, Steele P, Degruw T. (2002). Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res, 22:919–29.
   Web of Science ®Google Scholar
• Zaghloul AA, Gurley B, Khan M, Bhagavan H, Chopra R, Reddy I. (2002). Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Dev Ind Pharm, 28:1195–200.
   PubMed Web of Science ®Google Scholar
• Brancato R, Brancato R, Fiore T, Papucci L, Schiavone N, Formigli L, . (2002). Concomittant effect of topical ubiquinone Q10 and vitamin E to prevent keratocyte apoptosis after excimer lazer photoablation in rabbits. J Refract Surg, 18:135–9.
   PubMed Web of Science ®Google Scholar
• Prahl S, Kueper T, Biernoth T, Wöhrmann Y, Münster A, Fürstenau M, . (2008). Aging skin is functionally anaerobic: Importance of coenzyme Q(10) for anti aging skin care. Biofactors, 32:245–55.
   PubMed Web of Science ®Google Scholar
• Tang PH, Miles MV, DeGrauw A, Hershey A, Pesce A. (2001). HPLC analysis of reduced and oxidized coenzyme Q10 in human plasma. Clin Chem, 47:256–65.
   PubMed Web of Science ®Google Scholar
• Florence AT, Attwood D. (1998). Physicochemical principles of pharmacy, London: Macmillan Press.
   Google Scholar
• Raykar PV, Fung MC, Anderson BD. (1998). The role of protein and lipid domains in the uptake of solutes by human stratum corneum. Pharm Res, 5:140–50.
   Google Scholar
• Flynn GL. (1990). Physicochemical determinants of skin absorption. In: Gerrity TR, Henry CJ, eds. Principles of route-to-route extrapolation for risk assessment, Amsterdam, the Netherlands: Elsevier, Inc, p. 93–127.
   Google Scholar
• Cho YJ, Choi HK. (1998). Enhancement of percutaneous absorption of ketoprofen: Effect of vehicles and adhesive matrix. Int J Pharm, 169:95–104.
   Web of Science ®Google Scholar
• Gwak HS, Kim SU, Chun IK. (2002). Effect of vehicles and enhancers on the in vitro permeation of melatonin through hairless mouse skin. Arch Pharm Res, 25:392–6.
   PubMed Web of Science ®Google Scholar
• Gwak HS, Oh IS, Chun IK. (2004). Transdermal delivery of ondansetron hydrochloride: Effects of vehicles and penetration enhancers. Drug Dev Ind Pharm, 30:187–94.
   PubMed Web of Science ®Google Scholar
• Choi JS, Cho YA, Chun IK, Jung SY, Gwak HS. (2007). Formulation and evaluation of ketorolac transdermal systems. Drug Del, 14:69–74.
   PubMed Web of Science ®Google Scholar
• Kim TK, Kang EY, Chun IK, Gwak HS. (2008). Pharmacokinetics of formulated tenoxicam transdermal delivery systems. J Pharm Pharmacol, 60:135–8.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. (1998). Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharm Res, 6:244–7.
   Google Scholar
• Barry BW. (1987). Mode of action of penetration enhancers in human skin. J Control Release, 6:85–97.
   Google Scholar
• Golden GM, McKie JE, Potts RO. (1987). Role of stratum corneum lipid fluidity in transdermal drug flux. J Pharm Sci, 76:25–8.
   PubMed Web of Science ®Google Scholar